Brief: Emcure Pharmaceuticals Receives EIR From USFDA
18/04/2025 15:07
April 18 (Reuters) - Emcure Pharmaceuticals Ltd EMCU.NS: RECEIVES EIR FROM USFDA UPDATE ON USFDA INSPECTION AT API MANUFACTURING FACILITY AT KURKUMBH USFDA CLASSIFIES EMCURE'S FACILITY INSPECTION AS VAI Source text: ID:nNSE4qryTM Further company coverage: EMCU.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Emcure Pharmaceuticals
See all newsIndia's Emcure Pharma rises on Poviztra approval, Motilal initiation with 'buy'
Brief: Emcure Pharmaceuticals Ltd To Expand Use Of Poviztra For Mash Indication Following CDSCO Approval
Brief: Emcure Pharmaceuticals Says Kuber Jagdale, President, API Business, Superannuates
India's Emcure Pharma hits record high after Jefferies raises TP
Brief: Emcure Pharmaceuticals March-Quarter Consol Net Profit 2.43 Billion Rupees